Pharmacokinetic/pharmacodynamic antimicrobial individualization and optimization strategies

被引：2

作者：

Lim T.-P. ^{[1
]}

Garey K.W. ^{[1
]}

Tam V.H. ^{[1
]}

机构：

[1] University of Houston College of Pharmacy, Houston, TX 77030

来源：

Current Infectious Disease Reports | 2008年 / 10卷 / 1期

关键词：

Vancomycin; Antimicrob Agent; Intermittent Infusion; Microbiologic Outcome; Serum Drug Concentration;

D O I：

10.1007/s11908-008-0004-0

中图分类号：

学科分类号：

摘要：

Effective antimicrobiol chemotherapy integrates pharmacology and microbiology to achieve the most favorable clinical and microbiologic outcomes. Understanding such relationship allows us to select the optimal drug dose in a rational manner. The difficulty lies in translating the research findings to clinicians at the bedside. Current clinical practices have not embraced fully many advances in pharmacokinetic/pharmacodynamic research. This article summarizes what we have learned over the past decades and highlights some of the barriers to translating these results into clinical practice. Reducing these barriers would help to bring clinically relevant laboratory work to the bedside and would emphasize evidence-based medicine. It may also improve patient outcomes and minimize the emergence of resistance. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：9 / 13

页数：4

共 24 条

[1]

Andes D., Craig W.A., Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models, Antimicrob Agents Chemother, 46, pp. 1665-1670, (2002)

[2]

Craig W.A., Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men, Clin Infect Dis, 26, pp. 1-10, (1998)

[3]

Ferriols-Lisart R., Alos-Alminana M., Effectiveness and safety of once-daily aminoglycosides: A meta-analysis, Am J Health Syst Pharm, 53, pp. 1141-1150, (1996)

[4]

Rybak M.J., Abate B.J., Kang S.L., Et al., Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity, Antimicrob Agents Chemother, 43, pp. 1549-1555, (1999)

[5]

Murry K.R., McKinnon P.S., Mitrzyk B., Rybak M.J., Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside, Pharmacotherapy, 19, pp. 1252-1260, (1999)

[6]

Chuck S.K., Raber S.R., Rodvold K.A., Areff D., National survey of extended-interval aminoglycoside dosing, Clin Infect Dis, 30, pp. 433-439, (2000)

[7]

Hidayat L.K., Hsu D.I., Quist R., Et al., High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity, Arch Intern Med, 166, pp. 2138-2144, (2006)

[8]

Moise-Broder P.A., Sakoulas G., Forrest A., Schentag J.J., Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia, Antimicrob Agents Chemother, (2007)

[9]

Di Filippo A., De Gaudio A.R., Novelli A., Et al., Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection, Chemotherapy, 44, pp. 63-68, (1998)

[10]

Wysocki M., Delatour F., Faurisson F., Et al., Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study, Antimicrob Agents Chemother, 45, pp. 2460-2467, (2001)

← 1 2 3 →